Strategic AI Biotech Leverage Biosortia’s ISMM technology and AI-driven drug discovery platform to propose collaborations or co-development programs that accelerate lead identification and IND timelines for potential partners in oncology, immunotherapy, or CNS indications.

Industry Partnerships Target potential collaborations with large pharma and contract research organizations (CROs) such as Leidos or others seeking access to novel microbiome-derived compounds and AI-enabled screening to expand their infectious disease, cancer, or rare disease pipelines.

Funding & Grants Highlight ongoing and past funding momentum (ARPA-E grant history and total funding) to position as a financially solid partner for joint research initiatives, government-funded programs, or milestone-based collaborations with risk-sharing structures.

Early-Stage Pipeline Position Biosortia as a source of unique, drug-like natural products for early-stage lead generation and in silico screening, offering access to exclusive chemical diversity to de-risk discovery timelines for potential clients.

Market Readiness Emphasize rapid translation from computational prioritization to in vitro/in vivo exploration and potential IND readiness, presenting a compelling value proposition for biotech companies seeking faster path to clinical candidates.